698394-60-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-1-(4-ethylphenyl)-2-methylpropan-1-one is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs and medications.
Used in Agrochemical Industry:
2-Bromo-1-(4-ethylphenyl)-2-methylpropan-1-one is also utilized as an intermediate in the synthesis of agrochemicals, contributing to the development of pesticides, herbicides, and other agricultural products.
Used as a Reagent in Organic Synthesis:
2-Bromo-1-(4-ethylphenyl)-2-methylpropan-1-one serves as a reagent in organic synthesis, particularly in the preparation of complex organic molecules. Its unique properties and reactivity make it an essential tool for chemists working on advanced organic compounds and reactions.

Upstream product

• 20469-89-0 2-bromo-2-methylpropionyl chloride 
• 100-41-4 ethylbenzene 
• 20769-85-1 2-bromoisobutyric acid bromide 

Downstream Products

• 1256584-73-2 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid 
• 1247119-83-0 2-(4-ethylphenyl)-2-methyl-propanoic acid 
• 1256580-46-7 C⁽²⁴⁸⁾H₅₄₀₂ 
• 1256584-75-4 tert-butyl 6-cyano-2-[1-(4-ethyl-3-iodo-phenyl)-1-methyl-ethyl]-1H-indole-3-carboxylate 

Relevant academic research and scientific papers

Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)

A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (36 and 37) with pomalidomide through linkers of different lengths and types. The most promising degrader 17 possessed a high ALK-binding affinity and potent antiproliferative activity in the ALK-dependent cell lines and did not exhibit obvious cytotoxicity in ALK fusion-negative cells. More importantly, the efficacy of compound 17 in a Karpas 299 xenograft mouse model was further evaluated based on its ALK-sustained degradation ability in vivo. The reduction in tumor weight in the compound 17-treated group (10 mg/kg/day, I.V.) reached 75.82%, while alectinib reduced tumor weight by 63.82% at a dose of 20 mg/kg/day (P.O.). Taken together, our findings suggest that alectinib-based PROTACs associated with the degradation of ALK may have promising beneficial effects for treating ALK-driven malignancies.

A NOVEL PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF ALECTINIB

The present invention provides a novel process for the preparation of 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid of Formula (I), (I) which is a key intermediate in the synthesis of Alectinib or its salt of Formula (II).

Synthesis method for alectinib hydrochloride intermediate

The invention discloses a synthesis method for an alectinib hydrochloride intermediate. The synthesis method includes the following steps: 1) with 2-bromo-2-methylpropionic acid as an initial raw material, adding thionyl chloride to perform a chlorination reaction to obtain a compound (I); 2) adding ethylbenzene to the compound (I) and adding anhydrous aluminum trichloride as a catalyst to perform a substitution reaction to obtain a compound (II); 3) dissolving the compound (II) in an organic solvent, adding HC(OMe)3 and a catalyst ZnCl2, performing heat reflux until a rearrangement reaction is completely finished to obtain a compound (III); 4) dissolving the compound (III) in an organic solvent, adding iodine and iodic acid to perform a catalytic reaction to generate a compound (IV); and 5) under alkaline condition, hydrolyzing the compound (IV) to produce the target product, alectinib hydrochloride intermediate. The synthesis method is simple in operations, has high yield and is lower in cost.

Discovery of 6-phenylpyrimido[4,5- B ][1,4]oxazines as potent and selective Acyl CoA: Diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents

The discovery and optimization of a series of acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors based on a pyrimido[4,5-b][1,4]oxazine scaffold is described. The SAR of a moderately potent HTS hit was investigated resulting in the discovery of phenylcyclohexylacetic acid 1, which displayed good DGAT1 inhibitory activity, selectivity, and PK properties. During preclinical toxicity studies a metabolite of 1 was observed that was responsible for elevating the levels of liver enzymes ALT and AST. Subsequently, analogues were synthesized to preclude the formation of the toxic metabolite. This effort resulted in the discovery of spiroindane 42, which displayed significantly improved DGAT1 inhibition compared to 1. Spiroindane 42 was well tolerated in rodents in vivo, demonstrated efficacy in an oral triglyceride uptake study in mice, and had an acceptable safety profile in preclinical toxicity studies.